The global lung cancer market is expected to grow at a CAGR of around 14.2% from 2020 to 2027 and expected to reach the market value of around US$ 44,728.5 Mn by 2027.
Lung cancer is cancer that starts in the lungs. Lung cancer is the leading cause of death from cancer worldwide. The majority of lung cancers do not cause symptoms until they have spread, but some people with early lung cancer do. According to the American Cancer Society, there will be approximately 235,760 new cases of lung cancer in 2021. (119,100 in men and 116,660 in women). In addition, approximately 131,880 lung cancer deaths have been recorded (69,410 in men and 62,470 in women). Lung cancer is by far the leading cause of cancer death in both men and women, accounting for nearly 25% of all cancer deaths. Lung cancer kills more people each year than colon, breast, and prostate cancer combined.
What is new in lung cancer market?
As per the report released by the Lung Cancer Foundation of America., Biomarker testing is a key in today’s world of personalized medicine. Lung cancer biomarker testing, also known as genetic mutation testing, or genomic testing, looks for the mutations, or “specific biomarkers” in the cells of a tumor. These biomarkers can be used to help a lung cancer patient decide on the best course of treatment. A new study has identified a potential biomarker of early-stage non–small cell lung cancer, according to a report released by the United States Department of Health and Human Services in January 2019. (NSCLC). A protein called "SGLT2" is used to transport glucose into some cells and is a potential new biomarker. The biomarker could help noninvasively diagnose precancerous lung growths (called nodules or lesions) and early-stage lung cancers, as well as distinguish them from noncancerous lung nodules (benign).
Targeted therapies have gained huge significance in the global lung cancer market
Targeted treatments identify and attack specific types of cancer cells while causing less harm to healthy cells. Many targeted therapies for advanced lung cancer have become available in recent years, and more are in development. There are currently FDA-approved targeted therapies for lung cancer tumors with EGFR, ALK, ROS-1, NTRK, MET, RET, and BRAF V600E mutations. Additionally, it was not until the emergence of targeted therapy based on molecular typing that the survival period of patients with advanced NSCLC was improved to several years, such as the second generation ALK-TKI alectinib (Alecensa) achieved the PFS of first-line NSCLC patients with ALK fusion up to 34.8 months, and the adverse reactions were greatly reduced, such as the adverse events of grade 3 or higher was lower with the third generation EGFR-TKI osimertinib (Tagrisso, 23%) than with platinum-pemetrexed (47%).
Geriatric population more succumbed for developing lung cancer
Concerns about treatment tolerability, toxicity, and limited clinical trial data in the elderly impede treatment of elderly patients with lung cancer, potentially leading to treatment nihilism among clinicians. According to Cancer Facts and Figures, the leading causes of cancer death in the elderly are the same as those for all ages. Prostate and lung cancer are the leading causes of cancer death in men aged 85 and up, accounting for 40% of all cancer deaths. Lung cancer is the leading cause of cancer death among women (19%), followed by breast cancer (13%).
Rising prevalence of smoking among the population is more prone to develop lung cancer
In the United States, lung cancer is by far the leading cause of cancer death in both men and women. Smoking is also a major risk factor for lung cancer. According to data released by the Centers for Disease Control and Prevention, cigarette smoking is responsible for approximately 80% to 90% of lung cancers in the United States (CDC). Furthermore, in 2016, approximately 38 million adults smoked, and approximately 3 million high school and middle school students smoked in 2017. Despite the fact that the proportion of adult smokers is higher, the geographic patterns of cigarette use among adults and youth are similar. The states with the highest percentage of current adult smokers are concentrated in the Midwest, South, and Northeast.
The global lung cancer market is segmented as type, treatment, and end-user. By type, the market is segmented as SCLC and NSCLC. Further, treatment is segregated as surgery, chemotherapy, radiotherapy, photodynamic therapy (PDT), and laser therapy. By end-user, the market is segmented as hospitals & clinics, cancer research centers, and laboratories.
NSCLC has dominated the global lung cancer market by type in the past and is expected to do so again during the forecast period. According to the American Cancer Society, Inc., NSCLC is more prevalent in the population, accounting for approximately 84% of all cases. This is one of the most important factors that have a positive impact on segmental growth, ultimately contributing to the growth of the global lung cancer market.
The chemotherapy segment accounts for a significant portion of the global lung cancer market's growth in terms of treatment. Adjuvant chemotherapy is the accepted standard of care for certain patients with early-stage non–small cell lung cancer, according to several randomized trials and meta-analyses (NSCLC). Adjuvant chemotherapy is appropriate for patients with stage II, IIIA, or large (4 cm) IB tumors. Adjuvant chemotherapy improves survival by about 5% after 5 years, though some trials have suggested that it can be as high as 8% to 10%. Although the volume of data with this approach is far less than that with adjuvant chemotherapy, neoadjuvant chemotherapy has also shown a survival advantage.
North America dominates; Asia Pacific records fastest growing CAGR for the lung cancer market
The market for lung cancer is dominated by North America. The large share of North America can be attributed to rising technological advancements in lung cancer treatment, rising incidence and prevalence of lung cancer, rising trend of smoking tobacco, increasing emphasis on early cancer diagnosis and treatment, and reimbursement availability.
Asia Pacific, on the other hand, is expected to have the fastest growing CAGR in the lung cancer market. Rising regulatory approvals and increased adoption of advanced therapeutics in this region are important factors that contribute to regional growth, which in turn contributes to the growth of the lung cancer market.
The prominent players of the global lung cancer market involve F. Hoffmann-La Roche AG, AstraZeneca plc, Eli Lilly and Company, The Merck Group, Sanofi S.A., Pfizer Inc., GlaxoSmithKline, Boehringer Ingelheim GmbH, and among others
Market by Type
Market by Treatment
Photodynamic Therapy (PDT)
Market by End-User
Hospitals & Clinics
Cancer Research Centers
Market By Geography
• Rest of Europe
• South Korea
• Rest of Asia-Pacific
• Rest of Latin America
Middle East & Africa
• South Africa
• Rest of Middle East & Africa
Lung cancer market is expected to reach a market value of around US$ 44,728.5 Mn by 2027.
The lung cancer market is expected to grow at a CAGR of around 14.2% from 2020 to 2027.
Based on type, NSCLC segment is the leading segment in the overall market.
Rising prevalence of smoking among the population is one of the prominent factors that drive the demand for lung cancer market.
Which are the prominent players in the lung cancer market?
Which region held the highest market share in the lung cancer market?
Which region is expected to be the fastest growing market over the forecast period?